Skip to main content

Advertisement

Log in

Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin’s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rüdiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 13:140–9

    Article  PubMed  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D et al (2008) International T-cell lymphoma project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–30

    Article  PubMed  Google Scholar 

  3. [No authors listed] [2000] The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 50:696–702

  4. Weisenburger DD, Savage KJ, Harris NL et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 117:3402–8

    Article  CAS  PubMed  Google Scholar 

  5. Tomita N, Motomura S, Hyo R et al (2007) Comparison of peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Cancer 109:1146–51

    Article  PubMed  Google Scholar 

  6. Schmitz N, Trümper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116:3418–25

    Article  CAS  PubMed  Google Scholar 

  7. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–8

    Article  PubMed  Google Scholar 

  8. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–86

    Article  PubMed  Google Scholar 

  9. Haioun C, Itti E, Rahmouni A et al (2005) 18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–81

    Article  CAS  PubMed  Google Scholar 

  10. Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–9

    Article  CAS  PubMed  Google Scholar 

  11. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–52

    Article  CAS  PubMed  Google Scholar 

  12. Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626–32

    Article  PubMed  Google Scholar 

  13. Itti E, Lin C, Dupuis J et al (2009) Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50:527–33

    Article  PubMed  Google Scholar 

  14. Hadithi M, Mallant M, Oudejans J et al (2006) 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 47:1622–7

    PubMed  Google Scholar 

  15. Bishu S, Quigley JM, Schmitz J et al (2007) F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 48:1531–8

    Article  CAS  PubMed  Google Scholar 

  16. Kako S, Izutsu K, Ota Y et al (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–90

    Article  CAS  PubMed  Google Scholar 

  17. Karantanis D, Subramaniam RM, Peller PJ et al (2008) The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 8:94–9

    Article  PubMed  Google Scholar 

  18. Khong PL, Pang CB, Liang R et al (2008) Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87:613–21

    Article  PubMed  Google Scholar 

  19. Suh C, Kang YK, Roh JL et al (2008) Prognostic value of tumor 18 F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 49:1783–9

    Article  PubMed  Google Scholar 

  20. Wu HB, Wang QS, Wang MF et al (2010) Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun 31:195–200

    Article  PubMed  Google Scholar 

  21. Zinzani PL (2011) PET in T-cell lymphoma. Curr Hematol Malig Rep 6:241–4

    Article  PubMed  Google Scholar 

  22. [No authors listed] [1993] A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–94

  23. Gallamini A, Stelitano C, Calvi R et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–9

    Article  CAS  PubMed  Google Scholar 

  24. Tomita N, Kodama F, Tsuyama N et al (2014) Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma. Hematol Oncol (in press)

  25. Miller TP, Dahlberg S, Cassady JR et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21–6

    Article  CAS  PubMed  Google Scholar 

  26. Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas NCI sponsored international working group. J Clin Oncol 17:1244–53

    CAS  PubMed  Google Scholar 

  27. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′ -O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42:1462–7

    CAS  PubMed  Google Scholar 

  28. Savage KJ (2011) Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2011:515–24

    Article  PubMed  Google Scholar 

  29. Mori M, Kitamura K, Masuda M et al (2005) Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 81:246–54

    Article  CAS  PubMed  Google Scholar 

  30. Cahu X, Bodet-Milin C, Brissot E et al (2011) 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol 22:705–11

    Article  CAS  PubMed  Google Scholar 

  31. Li YJ, Li ZM, Xia XY et al (2013) Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med 54:507–15

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no competing financial interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naoto Tomita.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tomita, N., Hattori, Y., Fujisawa, S. et al. Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Ann Hematol 94, 431–436 (2015). https://doi.org/10.1007/s00277-014-2227-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2227-5

Keywords

Navigation